Directory
>
Kory Wentworth
Kory Wentworth
Chief Financial Officer and Treasurer | Entrada Therapeutics
Cambridge, Massachusetts, United States
Kory Wentworth
Summary
Kory Wentworth is a seasoned Chief Financial Officer with extensive experience in the biotechnology sector, particularly in high growth environments. He has a proven track record of leading cross-functional teams and managing complex financial operations, including SEC reporting and compliance. Kory has a strong background in both corporate finance and public accounting, having held key positions at notable firms such as Bluebird Bio and Alexion Pharmaceuticals. His leadership has been pivotal in supporting global product launches and operational scaling. Kory is known for fostering a culture of continuous improvement, implementing robust internal controls, and driving strategic financial initiatives. He is dedicated to developing high-performing finance teams and enhancing financial reporting processes. With a solid educational foundation in accounting, Kory is also a member of professional organizations like AICPA and CSCPA. His diverse experience across various financial roles equips him with a unique perspective on the challenges and opportunities in the finance landscape.
Kory Wentworth
Work Experience
Chief Financial Officer and Treasurer at
Entrada Therapeutics
November 2020 - Present
Vice President, Finance and Treasurer, Principal Accounting Officer at
bluebird bio
December 2017 - October 2020
Executive Director & Corporate Controller at
Alexion Pharmaceuticals, Inc.
December 2008 - December 2017
Audit manager at
PwC
October 2002 - December 2008
Associate – Government Assurance Practice at
KPMG Nigeria
June 2002 - August 2002
Associate – Assurance and Advisory Business Services at
Arthur Andersen (1885 -> 2002) Official
September 2001 - April 2002
Kory Wentworth
Education
Susquehanna University, Bachelor's Degree
January 1997 - January 2001
Thornton Academy
January 1994 - January 1997
Frequently Asked Questions about Kory Wentworth
What is Kory Wentworth email address?
Kory Wentworth's primary email address is **********@entradatx.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Kory Wentworth work for?
Kory Wentworth is a Chief Financial Officer and Treasurer at Entrada Therapeutics, a company specializing in Commercial physical research.
Where Kory Wentworth graduated from?
Kory Wentworth holds a degree in Accounting from Susquehanna University.
How can I directly contact Kory Wentworth?
To contact Kory Wentworth directly, you can use the email address **********@entradatx.com. Complete contact information is available upon registration with Muraena.
Who is Kory Wentworth?
Kory Wentworth is a seasoned Chief Financial Officer with extensive experience in the biotechnology sector, particularly in high growth environments. He has a proven track record of leading cross-functional teams and managing complex financial operations, including SEC reporting and compliance. Kory has a strong background in both corporate finance and public accounting, having held key positions at notable firms such as Bluebird Bio and Alexion Pharmaceuticals. His leadership has been pivotal in supporting global product launches and operational scaling. Kory is known for fostering a culture of continuous improvement, implementing robust internal controls, and driving strategic financial initiatives. He is dedicated to developing high-performing finance teams and enhancing financial reporting processes. With a solid educational foundation in accounting, Kory is also a member of professional organizations like AICPA and CSCPA. His diverse experience across various financial roles equips him with a unique perspective on the challenges and opportunities in the finance landscape.
Kory`s contact details
**********@entradatx.com
Colleagues
Vice President
Executive Director, FP&A
Executive Director
Vice President, Head of Cardiovascular and Neuromuscular & Cardiovascular Therapeutics
Board Member
Co-Founder & Vice President, Discovery Research
Vice President | Head of CMC
President Research And Development at Entrada Therapeutics
President and Chief Operating Officer
VP, Program Governance & Portfolio Management